CA2355644A1 - Formulations orales de methylphenidate a liberation regulee/modifiee - Google Patents
Formulations orales de methylphenidate a liberation regulee/modifiee Download PDFInfo
- Publication number
- CA2355644A1 CA2355644A1 CA002355644A CA2355644A CA2355644A1 CA 2355644 A1 CA2355644 A1 CA 2355644A1 CA 002355644 A CA002355644 A CA 002355644A CA 2355644 A CA2355644 A CA 2355644A CA 2355644 A1 CA2355644 A1 CA 2355644A1
- Authority
- CA
- Canada
- Prior art keywords
- controlled
- methylphenidate formulations
- modified release
- release oral
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11266798P | 1998-12-17 | 1998-12-17 | |
US60/112,667 | 1998-12-17 | ||
PCT/US1999/030305 WO2000035450A1 (fr) | 1998-12-17 | 1999-12-17 | Formulations orales de methylphenidate a liberation regulee/modifiee |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2355644A1 true CA2355644A1 (fr) | 2000-06-22 |
CA2355644C CA2355644C (fr) | 2009-01-20 |
Family
ID=22345214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002355644A Expired - Lifetime CA2355644C (fr) | 1998-12-17 | 1999-12-17 | Formulations orales de methylphenidate a liberation regulee/modifiee |
Country Status (15)
Country | Link |
---|---|
US (1) | US6673367B1 (fr) |
EP (2) | EP1967191B8 (fr) |
JP (3) | JP4663880B2 (fr) |
AT (1) | ATE395916T1 (fr) |
AU (1) | AU2371200A (fr) |
CA (1) | CA2355644C (fr) |
CY (2) | CY1108253T1 (fr) |
DE (1) | DE69938791D1 (fr) |
DK (2) | DK1140088T3 (fr) |
ES (2) | ES2586611T3 (fr) |
HK (1) | HK1124257A1 (fr) |
LT (1) | LT1967191T (fr) |
PT (2) | PT1967191T (fr) |
SI (2) | SI1140088T1 (fr) |
WO (1) | WO2000035450A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009117819A1 (fr) * | 2008-03-27 | 2009-10-01 | Pharmascience Inc. | Système de délivrance de méthylphénidate à libération étendue |
WO2010015029A1 (fr) | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions et procédés de traitement de troubles psychiatriques |
WO2013007698A1 (fr) | 2011-07-08 | 2013-01-17 | Gosforth Centre (Holdings) Pty Ltd | Composition pharmaceutique pour troubles neurologiques |
WO2016065481A1 (fr) * | 2014-10-31 | 2016-05-06 | Purdue Pharma | Méthodes et compositions destinées en particulier au traitement du trouble déficitaire de l'attention |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004200325B2 (en) * | 1998-10-21 | 2006-09-28 | Shire Llc | Oral Pulsed Dose Drug Delivery System |
US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US6673367B1 (en) * | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
US7083808B2 (en) * | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
US6344215B1 (en) * | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
JP2006516948A (ja) * | 2000-11-14 | 2006-07-13 | ニュー リバー ファーマシューティカルズ インコーポレイテッド | 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法 |
FR2818552B1 (fr) * | 2000-12-26 | 2003-02-07 | Servier Lab | Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine |
US20020187192A1 (en) * | 2001-04-30 | 2002-12-12 | Yatindra Joshi | Pharmaceutical composition which reduces or eliminates drug abuse potential |
DE10208344A1 (de) * | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Schmelzextrusion von Wirkstoffsalzen |
CA2395819A1 (fr) * | 2002-08-13 | 2004-02-13 | Bernard Charles Sherman | Formulation a liberation en deux etapes pour la dispensation de medicaments peroraux |
US6913768B2 (en) | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US7988993B2 (en) * | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
WO2004100883A2 (fr) * | 2003-05-06 | 2004-11-25 | Bpsi Holdings, Inc. | Procede de preparation de compositions thermoformees contenant des liants de polymere acrylique, des posologies pharmaceutiques et leurs procedes de preparation |
CA2529984C (fr) | 2003-06-26 | 2012-09-25 | Isa Odidi | Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif |
WO2005044238A1 (fr) * | 2003-11-07 | 2005-05-19 | Ranbaxy Laboratories Limited | Formes posologiques solides a liberation modifiee de sels d'amphetamine |
US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US20060024361A1 (en) * | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
DK2036546T3 (en) * | 2004-08-23 | 2018-12-17 | Pejo Iserlohn Heilmittel Und Diaet Gmbh & Co Kg | Psychostimulants containing a pharmaceutical composition |
US10624858B2 (en) * | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
EP2428205B1 (fr) | 2006-03-16 | 2012-10-03 | Tris Pharma, Inc. | Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions |
US9561188B2 (en) * | 2006-04-03 | 2017-02-07 | Intellipharmaceutics Corporation | Controlled release delivery device comprising an organosol coat |
JP5349290B2 (ja) * | 2006-04-03 | 2013-11-20 | オディディ,イサ | 薬物送達組成物およびそれを含む医薬品、ならびにその製造方法 |
EP2457562B1 (fr) | 2006-05-09 | 2017-04-05 | Mallinckrodt LLC | Formes posologiques solides à libération modifiée d'ordre zéro |
US8846100B2 (en) | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
AU2007275034A1 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
DE102007009242A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
EP2144599B1 (fr) * | 2007-03-02 | 2010-08-04 | Farnam Companies, Inc. | Granules à libération prolongée utilisant des matières cireuses |
CA2697189A1 (fr) * | 2007-09-12 | 2009-03-19 | Elan Pharma International Limited | Schema posologique |
KR101264961B1 (ko) * | 2008-11-07 | 2013-05-16 | 주식회사 삼양바이오팜 | 메칠페니데이트의 방출 제어용 약제학적 조성물 |
US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
US9561241B1 (en) * | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
WO2014174387A1 (fr) * | 2013-03-29 | 2014-10-30 | Wockhardt Limited | Compositions pharmaceutiques à libération modifiée de dexméthylphénidate ou de sels de celui-ci |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
EP3372225A1 (fr) * | 2017-03-09 | 2018-09-12 | Develco Pharma Schweiz AG | Nouvelle forme posologique |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
JPS55149211A (en) * | 1979-05-10 | 1980-11-20 | Takeda Chem Ind Ltd | Production of gradually releasable preparation |
GB2186485B (en) * | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
AU591248B2 (en) | 1986-03-27 | 1989-11-30 | Kinaform Technology, Inc. | Sustained-release pharaceutical preparation |
GB8613689D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
IT1213080B (it) * | 1986-06-17 | 1989-12-07 | Recordati Chem Pharm | Sistemi terapeutico per la cessione controllata di farmaci. |
EP0325086A3 (fr) * | 1987-11-23 | 1990-10-31 | Jago Research Ag | Méthodes pour obtenir des systèmes thérapeutiques à libération contrôlée du médicament |
DE3827214A1 (de) * | 1988-08-11 | 1990-02-15 | Roehm Gmbh | Retardierte arzneiform und verfahren zu ihrer herstellung |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
AU1992592A (en) | 1991-05-24 | 1993-01-08 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
EP0520119A1 (fr) | 1991-06-17 | 1992-12-30 | Spirig Ag Pharmazeutische Präparate | Composition à base de diclofenac pour l'administration orale |
US5326570A (en) | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5286493A (en) | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US6077533A (en) | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
JPH11509227A (ja) | 1995-07-14 | 1999-08-17 | カイロサイエンス・リミテッド | d−トレオ−メチルフェニデートの治療的使用 |
GB9514451D0 (en) * | 1995-07-14 | 1995-09-13 | Chiroscience Ltd | Sustained-release formulation |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
IL123505A (en) | 1996-07-08 | 2004-12-15 | Penwest Pharmaceuticals Compan | Sustained release matrix for high-dose insoluble drugs |
CN101518517B (zh) * | 1996-08-16 | 2014-11-26 | 阿尔萨公司 | 药物剂量逐渐增加的剂型 |
DE69735581T2 (de) * | 1996-09-30 | 2007-01-25 | Alza Corp., Palo Alto | Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung |
CN100477986C (zh) | 1996-11-25 | 2009-04-15 | 阿尔萨公司 | 递增剂量的剂型 |
US5945123A (en) * | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
ES2229783T3 (es) | 1998-06-03 | 2005-04-16 | Alza Corporation | Dispositivos para proporcionar una terapia faramaceutica prolongada. |
IL142896A0 (en) | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
US6673367B1 (en) * | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
-
1999
- 1999-12-16 US US09/465,158 patent/US6673367B1/en not_active Expired - Lifetime
- 1999-12-17 JP JP2000587770A patent/JP4663880B2/ja not_active Expired - Lifetime
- 1999-12-17 PT PT81563975T patent/PT1967191T/pt unknown
- 1999-12-17 LT LTEP08156397.5T patent/LT1967191T/lt unknown
- 1999-12-17 EP EP08156397.5A patent/EP1967191B8/fr not_active Expired - Lifetime
- 1999-12-17 CA CA002355644A patent/CA2355644C/fr not_active Expired - Lifetime
- 1999-12-17 DK DK99967438T patent/DK1140088T3/da active
- 1999-12-17 AT AT99967438T patent/ATE395916T1/de active
- 1999-12-17 AU AU23712/00A patent/AU2371200A/en not_active Abandoned
- 1999-12-17 ES ES08156397.5T patent/ES2586611T3/es not_active Expired - Lifetime
- 1999-12-17 WO PCT/US1999/030305 patent/WO2000035450A1/fr active Application Filing
- 1999-12-17 EP EP99967438A patent/EP1140088B1/fr not_active Revoked
- 1999-12-17 DK DK08156397.5T patent/DK1967191T3/en active
- 1999-12-17 ES ES99967438T patent/ES2306535T3/es not_active Expired - Lifetime
- 1999-12-17 SI SI9931015T patent/SI1140088T1/sl unknown
- 1999-12-17 PT PT99967438T patent/PT1140088E/pt unknown
- 1999-12-17 SI SI9931081A patent/SI1967191T1/sl unknown
- 1999-12-17 DE DE69938791T patent/DE69938791D1/de not_active Expired - Lifetime
-
2006
- 2006-11-22 JP JP2006315261A patent/JP5186100B2/ja not_active Expired - Lifetime
-
2008
- 2008-08-12 CY CY20081100849T patent/CY1108253T1/el unknown
-
2009
- 2009-03-10 HK HK09102282.4A patent/HK1124257A1/zh not_active IP Right Cessation
-
2012
- 2012-04-19 JP JP2012095985A patent/JP5844676B2/ja not_active Expired - Lifetime
-
2016
- 2016-07-27 CY CY20161100738T patent/CY1117845T1/el unknown
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009117819A1 (fr) * | 2008-03-27 | 2009-10-01 | Pharmascience Inc. | Système de délivrance de méthylphénidate à libération étendue |
WO2010015029A1 (fr) | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions et procédés de traitement de troubles psychiatriques |
WO2013007698A1 (fr) | 2011-07-08 | 2013-01-17 | Gosforth Centre (Holdings) Pty Ltd | Composition pharmaceutique pour troubles neurologiques |
US10449159B2 (en) | 2014-10-31 | 2019-10-22 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10507186B2 (en) | 2014-10-31 | 2019-12-17 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10111839B2 (en) | 2014-10-31 | 2018-10-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10292939B2 (en) | 2014-10-31 | 2019-05-21 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10292938B2 (en) | 2014-10-31 | 2019-05-21 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
WO2016065481A1 (fr) * | 2014-10-31 | 2016-05-06 | Purdue Pharma | Méthodes et compositions destinées en particulier au traitement du trouble déficitaire de l'attention |
US10500162B2 (en) | 2014-10-31 | 2019-12-10 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US9974752B2 (en) | 2014-10-31 | 2018-05-22 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10512613B2 (en) | 2014-10-31 | 2019-12-24 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10512612B2 (en) | 2014-10-31 | 2019-12-24 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10568841B2 (en) | 2014-10-31 | 2020-02-25 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10688060B2 (en) | 2014-10-31 | 2020-06-23 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US11896722B2 (en) | 2014-10-31 | 2024-02-13 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
EA038198B1 (ru) * | 2014-10-31 | 2021-07-22 | Пердью Фарма | Способы и композиции, в частности, для лечения синдрома дефицита внимания |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Also Published As
Publication number | Publication date |
---|---|
CY1108253T1 (el) | 2014-02-12 |
JP2012184235A (ja) | 2012-09-27 |
JP5844676B2 (ja) | 2016-01-20 |
DK1967191T3 (en) | 2016-08-22 |
JP5186100B2 (ja) | 2013-04-17 |
ES2306535T3 (es) | 2008-11-01 |
EP1967191B8 (fr) | 2016-07-20 |
EP1140088A4 (fr) | 2003-03-19 |
CY1117845T1 (el) | 2017-05-17 |
DE69938791D1 (de) | 2008-07-03 |
JP2002532426A (ja) | 2002-10-02 |
CA2355644C (fr) | 2009-01-20 |
ATE395916T1 (de) | 2008-06-15 |
PT1140088E (pt) | 2008-07-16 |
LT1967191T (lt) | 2016-09-12 |
EP1967191A1 (fr) | 2008-09-10 |
ES2586611T3 (es) | 2016-10-17 |
EP1140088A1 (fr) | 2001-10-10 |
JP2007119479A (ja) | 2007-05-17 |
SI1967191T1 (sl) | 2016-09-30 |
SI1140088T1 (sl) | 2008-10-31 |
EP1967191B1 (fr) | 2016-05-18 |
DK1140088T3 (da) | 2008-09-15 |
PT1967191T (pt) | 2016-07-27 |
EP1140088B1 (fr) | 2008-05-21 |
HK1124257A1 (zh) | 2009-07-10 |
US6673367B1 (en) | 2004-01-06 |
JP4663880B2 (ja) | 2011-04-06 |
WO2000035450A1 (fr) | 2000-06-22 |
AU2371200A (en) | 2000-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2355644A1 (fr) | Formulations orales de methylphenidate a liberation regulee/modifiee | |
CA2355854A1 (fr) | Formulations a liberation controlee caracterisees par une action immediate et une diminution rapide des concentrations efficaces de medicaments dans le plasma | |
AU2001249329A1 (en) | Lipoxin analogs and methods for the treatment of periodontal disease | |
MXPA03003895A (es) | Formulaciones de hidrocodona de liberacion controlada. | |
CA2201264A1 (fr) | Forme posologique solide de cisapride, independante du ph et a liberation immediate | |
HUP0402113A3 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof | |
PL333524A1 (en) | Improved prolonged release pharmaceutic preparation for administration of nephadosone, oral dosage form thereof and improved nephadosone administration method | |
PL398391A1 (pl) | Koniugat hydroksyalkiloskrobi i polipeptydu, sposób wytwarzania tego koniugatu, jego zastosowanie oraz kompozycja farmaceutyczna zawierająca koniugat hydroksyalkiloskrobi i polipeptydu | |
HUP0203597A3 (en) | Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use | |
AU2001266152A1 (en) | Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them | |
NZ514129A (en) | Tolperison-containing, pharmaceutical preparation for oral administration | |
IL159067A0 (en) | METHODS FOR PREPARATION AND USE OF 1alpha,24 (S) -DIHYDROXYVITAMIN D2 | |
GB2369617B (en) | Novel 4,5-dihydroisoxazolylalkyl-piperazine or-piperidine derivatives having selective biological activity at dopamine D3orD4 receptor,and preparation thereof | |
AU2001257406A1 (en) | Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941 | |
HUP0400495A3 (en) | Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue | |
IL158587A0 (en) | Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof | |
HUP0103686A2 (en) | Use of rolipram, ariflo or diazepino-indole, triazolo-quinazoline derivatives for the preparation of pharmaceutical compositions preventing or treating diseases associated with an excess in il-12 production | |
AU2002311623A1 (en) | Process for the preparation of 1,4-dihydropyridines and novel 1,4-dihydropyridines useful as therapeutic agents | |
AU2002239505A1 (en) | Methods and compositions for the diagnosis and treatment of viral disease using 55092 | |
HU0104622D0 (en) | Human influenza vaccine composition with increased activity and process for the preparation thereof | |
GB2375535B (en) | Methods of preparing 2,6-dimethyl-4-oxo-heptanoic acid and its use as a flavouring agent | |
HUP0204150A3 (en) | Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate, process for its preparation and pharmaceutical compositions containing the same | |
IL140127A0 (en) | Process for the preparation of optically active 1,4-benzodixoane-2-carboxylic acid and derivatives thereof | |
GB0030587D0 (en) | Oral administration of beneficial substances | |
AU2002341121A1 (en) | Binary composition for "prime-boost" release of active ingredients like vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20191217 |